(Q39443721)

English

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 September 2017

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination (English)

1 reference

Europe PubMed Central

12 September 2017

phase I clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

Michael Millward

1

1 reference

Europe PubMed Central

12 September 2017

Timothy Price

2

1 reference

Europe PubMed Central

12 September 2017

Amanda Townsend

3

1 reference

Europe PubMed Central

12 September 2017

Christopher Sweeney

4

1 reference

Europe PubMed Central

12 September 2017

Andrew Spencer

5

1 reference

Europe PubMed Central

12 September 2017

Shawgi Sukumaran

6

1 reference

Europe PubMed Central

12 September 2017

Angie Longenecker

7

1 reference

Europe PubMed Central

12 September 2017

Lonnie Lee

8

1 reference

Europe PubMed Central

12 September 2017

Ana Lay

9

1 reference

Europe PubMed Central

12 September 2017

Girish Sharma

10

1 reference

Europe PubMed Central

12 September 2017

Robert M Gemmill

11

1 reference

Europe PubMed Central

12 September 2017

Harry A Drabkin

12

1 reference

Europe PubMed Central

12 September 2017

G Kenneth Lloyd

13

1 reference

Europe PubMed Central

12 September 2017

Saskia T C Neuteboom

14

1 reference

Europe PubMed Central

12 September 2017

David J McConkey

15

1 reference

Europe PubMed Central

12 September 2017

Michael A Palladino

16

1 reference

Europe PubMed Central

12 September 2017

Matthew A Spear

17

1 reference

Europe PubMed Central

12 September 2017

publication date

12 November 2011

1 reference

Europe PubMed Central

12 September 2017

Investigational New Drugs

1 reference

Europe PubMed Central

12 September 2017

30

1 reference

Europe PubMed Central

12 September 2017

2303-2317

1 reference

Europe PubMed Central

12 September 2017

6

1 reference

Europe PubMed Central

12 September 2017

https://scigraph.springernature.com/pub.10.1007/s10637-011-9766-6

0 references

Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9766-6

21 January 2018

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9766-6

21 January 2018

Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9766-6

21 January 2018

Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9766-6

21 January 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9766-6

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9766-6

21 January 2018

NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9766-6

21 January 2018

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9766-6

21 January 2018

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9766-6

21 January 2018

Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9766-6

21 January 2018

A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9766-6

21 January 2018

Proteasome and HDAC: who's zooming who?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22080430

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Accelerated titration designs for phase I clinical trials in oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/22080430

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-011-9766-6

1 reference

Europe PubMed Central

12 September 2017

1 reference

Europe PubMed Central

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39443721&oldid=1828508529"